Compare SEE & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEE | RYTM |
|---|---|---|
| Founded | 1960 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.2B |
| IPO Year | 1996 | 2017 |
| Metric | SEE | RYTM |
|---|---|---|
| Price | $42.15 | $88.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $43.50 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 3.3M | 672.7K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 89.50 | 28.34 |
| EPS | ★ 3.43 | N/A |
| Revenue | ★ $5,359,800,000.00 | N/A |
| Revenue This Year | $1.93 | $55.34 |
| Revenue Next Year | $2.27 | $86.06 |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.15 | $58.71 |
| 52 Week High | $44.27 | $122.20 |
| Indicator | SEE | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 65.73 | 48.61 |
| Support Level | $41.79 | $87.19 |
| Resistance Level | $42.21 | $92.17 |
| Average True Range (ATR) | 0.08 | 4.80 |
| MACD | 0.02 | -0.24 |
| Stochastic Oscillator | 100.00 | 23.44 |
Sealed Air Corp is a provider of packaging solutions that integrate sustainable, high-performance materials, automation, equipment, and services. The company designs, manufactures, and delivers packaging solutions that preserve food, protect goods, and automate packaging processes. It delivers its packaging solutions to an array of end markets including fresh proteins, foods, fluids and liquids, medical and life science, e-commerce retail, logistics and omnichannel fulfillment operations, and industrials. It has two reportable segments, Food and Protective. The company generates majority of its revenue from the food segment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.